Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

121.72 +0.50 (+0.41%)
Streaming Delayed Price Updated: 9:39 AM EST, Dec 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
68 69 Next >
News headline image
Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update ↗
Earlier today, Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus... 
Via Benzinga
News headline image
How Roche's Accidental Cancer Update Lifted Iteos And Arcus More Than 30% ↗
Roche provided an update from its study in lung cancer using an anti-TIGIT drug. 
Via Investor's Business Daily
San Francisco Business Times Names Landis Communications Inc. (Landis) the Top 2022 Bay Area Corporate Philanthropist as a Percentage Of Profits
--News Direct-- 
Via News Direct
Topics LGBTQ
News headline image
Large Cap Biopharmaceuticals Performance 2023 YTD: Mixed Results But Lilly Is A Big Winner ↗
Biotech stocks are in a bear market since the IBB hit $177.37 in 2021 and is down 7.84% over five years. 
Via Talk Markets
News headline image
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About Gilead Sciences? ↗
 
Via Benzinga
News headline image
2 High-Yield Dividend Stocks to Buy on the Dip ↗
The market may have been a bit too harsh on these stocks. 
Via The Motley Fool
News headline image
FDA Pauses Gilead's Investigational Magrolimab Study In Blood Cancer Patients ↗
FDA has placed a partial clinical hold on Gilead Sciences Inc (NASDAQ: GILD) initiation of new patients in U.S. 
Via Benzinga
News headline image
5 Safe Stocks Under $40 to Buy Immediately ↗
Investors are turning away from risky bets and putting their money in safe stocks this week. Here are four names under $40 to buy now. 
Via InvestorPlace
News headline image
Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative® on HIV in the Southern United States
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences (GILD) Q2 2023 Earnings Call Transcript ↗
GILD earnings call for the period ending June 30, 2023. 
Via The Motley Fool
News headline image
Will An Earnings Miss Cloud Gilead's Massive Cancer Treatment Growth? ↗
Gilead missed earnings expectations Thursday, though reported strong sales growth for cancer drugs. 
Via Investor's Business Daily
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Autolus Therapeutics' Obe-Cel's Shows Compelling Safety Over Gilead's Drug For Acute Lymphoblastic Leukemia ↗
Truist has raised the price target for Autolus Therapeutics PLC (NASDAQ: AUTL) from $6 to $9  
Via Benzinga
News headline image
Gilead and Tentarix to Discover and Develop Novel Therapies to Address Unmet Medical Needs Across Cancer and Inflammation
From Gilead Sciences, Inc.
Via Business Wire
News headline image
The 3 Best Biotech Stocks to Buy in August ↗
Even as healthcare stocks suffer from post-pandemic fatigue, these three of the best biotech stocks to buy and ride the wave of good news. 
Via InvestorPlace
News headline image
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Hypertrophic Cardiomyopathy Therapeutics Market Projected to Show Strong Growth : Novartis, Gilead Sciences, ADVANZ PHARMA
Stay up-to-date with Hypertrophic Cardiomyopathy Therapeutics Market research offered by AMA. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
News headline image
Gilead Stock Jumps On Strong Q2 Performance Despite Lower Profit Outlook Amid Litigation ↗
Gilead Sciences Inc's (NASDAQ: GILD) Q2 FY23 sales increased 6% Y/Y to $6.60 billion, above the consensus of $6.43 billion, primarily driven by increased sales in HIV and Oncology, partially offset by... 
Via Benzinga
News headline image
Gilead Sciences Announces Second Quarter 2023 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
News headline image
US Stock Futures Dip As Apple, Amazon Earnings Loom: Analyst Warns Of 'Perfectly Normal' 5% Pullback This Month ↗
Stocks appear to be entrenched in an August swoon and it remains to be seen if big tech earnings provide a boost. 
Via Benzinga
News headline image
Market Rally Under Pressure As Yields Soar; Amazon, ELF, Caterpillar Are Earnings Winners: Weekly Review ↗
Amazon, ELF and CAT were earnings winners, but there were big losers too. 
Via Investor's Business Daily
News headline image
Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points ↗
Investors looking to give their portfolio a boost should consider one of these leading biotech names, which are undervalued right now. 
Via InvestorPlace
News headline image
3 Stocks Retirees Should Absolutely Love ↗
These stocks offer solid income plus more. 
Via The Motley Fool
News headline image
7 Best Cancer Stocks to Invest in Now
The second-largest cause of death in the U.S., more than 600,000 deaths from cancer will occur in 2023. Learn about the best cancer stocks to invest in now. 
Via MarketBeat
Topics Death
News headline image
European Commission Approves Gilead’s Trodelvy® For Pre-Treated HR+/HER2- Metastatic Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Trial Setback For Gilead Sciences: Shuts Late-Stage Magrolimab/Azacitidine Combo Study In Type Of Blood Cancer ↗
Gilead Sciences Inc (NASDAQ: GILD) decided to discontinue the Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes (MDS) due to futility  
Via Benzinga
News headline image
Bank of America, Bank of New York Mellon And 2 Other Stocks Insiders Are Selling ↗
The Nasdaq 100 closed slightly higher on Friday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
68 69 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.